Few studies have examined cytomegalovirus (CMV) reactivation exclusively in immunocompetent patients with sepsis due to bloodstream infections. In a cohort of CMV-seropositive critically ill otherwise non-immunosuppressed patients with sepsis due to bloodstream infection, weekly testing for CMV viraemia was performed. Outcomes were assessed at 30 days or until death/discharge from the intensive care unit (ICU). CMV viraemia developed in 20% (20/100) of the patients. Age (P=0.044) and blood transfusions (P=0.022) were significantly associated with CMV viraemia. There was no difference in the primary endpoint (mortality and/or multi-organ failure) between patients with and without CMV viraemia (P=0.49). However, CMV viraemia was associated with significantly fewer ICU-free days (P=0.023) and fewer ventilator-free days (P=0.031). Patients hospitalised in the ICU for more than 48 hours prior to the onset of bloodstream infection were more likely to develop CMV viraemia (P=0.006), have high-grade viraemia (P=0.010), and fewer ICU-free days (P=0.018) and ventilator-free days (P=0.029) than those admitted within 48 hours of bloodstream infection. Thus, CMV reactivation was associated with fewer ICU-and ventilator-free days, however overall mortality was not affected. Patients already in the ICU at the onset of sepsis had higher risk of CMV reactivation and worse outcomes than new ICU-bound patients suggesting that a targeted approach for interventions for CMV could conceivably be directed towards those with a more protracted course of illness.
Introduction
Cytomegalovirus (CMV) is a major β herpes virus and a significant human pathogen. Antibody to CMV, indicative of prior and latent infection, is common in the general population with rates of ~60%-70% in the United States and higher in other parts of the world 1 . Seroprevalence increases steadily from 65% among 40-49-year-olds to 91% in those 80 years of age or older 1 . Latent infection has the potential to activate and produce lytic virus. In immunologically competent patients, virus can be detected in body fluids such as urine and saliva, however shedding is usually asymptomatic and rarely of clinical relevance 2 . On the other hand, reactivation of CMV (viraemia) and its association with poor outcomes and higher resource utilisation has been well described in hosts with impaired immunity such as transplant recipients 3, 4 .
Critically ill patients who do not have overt immunosuppression are also at risk for CMV infection, and reactivation of CMV in these patients may be a contributor to poor outcomes [5] [6] [7] . However, existing data on CMV reactivation in this host population have shown inconsistent results depending upon the diagnostic assay employed, heterogeneity in the patient population studied, and the timing and rigour of assessments [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Previous studies using culture-based methodology may have underestimated the rates of CMV infection [12] [13] [14] [15] [16] [17] [18] [19] . Reactivation rates are also influenced by the characteristics of the study population, with greater impact documented, for example, in patients with sepsis and burns compared to those in the intensive care unit (ICU) after cardiac surgery 6 .
Sepsis accounts for ~225,000 deaths annually in the US; overall mortality rates in ICU patients with sepsis range from 20%-50% 20 . In patients with multiple organ system failure, the mortality rates are as high as 65%-76% 20 . Sepsis also leads to a significant increase in hospital costs and resource utilisation. The average cost of treating a critically ill patient with sepsis is US$29,900 and increases to US$32,800 in those with multiple organ failure 20 . However, few studies Anaesth Intensive Care 2016 | 44: 5 have systematically examined CMV reactivation with exclusive focus on critically ill patients with sepsis due to bloodstream infection (BSI) using quantitative molecular diagnostic assays 7, 15, 21 . The goals of this study therefore, were to assess reactivation of CMV and meaningful outcomes in a prospectively followed cohort of critically ill patients with sepsis and bloodstream infection.
Methods

Study design
This was a prospective, observational study involving critically ill patients with sepsis due to BSI conducted between December 2008 and June 2014 in the intensive care units of two university-affiliated academic medical centres. The study was approved by the institutional review board (University of Pittsburgh and VA Pittsburgh IRB numbers REN14110209/PRO08070448 and ID # 02709 respectively) and written informed consent was obtained from all patients or their legally authorised representatives.
Patients
Septic patients with BSI were eligible for the study if, i) they were ≥18 years of age, and ii) hospitalised in intensive care units at the time of or within 48 hours of the onset of BSI. Patients were considered to have sepsis due to BSI if they met previously defined International Sepsis Definition criteria for sepsis 22 and had at least one positive blood culture due to microorganisms other than coagulase-negative Staphylococci, Bacillus species, or diphtheroids as per Centers for Disease Control and Prevention criteria for bacteraemia 23 . Intravascular catheter-related bacteraemia or bacteraemia not related to an infection at another site was regarded as primary bacteraemia. Patients were considered to be immunocompetent if they had no known or overt evidence of immunosuppression. Patients were excluded if they were immunosuppressed as a result of organ transplantation or haematopoietic stem cell transplantation; human immunodeficiency virus (HIV) infection; receipt of iatrogenic immunosuppressive agents, defined as use of prednisone at a dose of >0.5 mg/kg/day for at least two weeks prior, tumour necrosis factor antagonists, methotrexate, or cancer chemotherapy within four weeks prior; or receipt of antiviral medications with activity against CMV, i.e. ganciclovir or valganciclovir.
After obtaining informed consent, a screening test for CMV antibody to determine CMV serostatus was performed using a commercially available immunoassay per manufacturer's instructions (bioMérieux™ Vidas® CMV IgG, Durham, NC, USA). Only CMV seropositive patients were enrolled; no further study procedures were conducted on CMV seronegative patients. Patients seropositive for CMV underwent weekly assessment for CMV viraemia using polymerase chain reaction (PCR) for 30 days from the date of positive blood culture or until death or discharge from the ICU. CMV assays were performed using whole blood quantitative real-time PCR as previously reported 24, 25 . Viral load represented CMV DNA copies/ml. The assay's range for the detection of CMV was 50 to 10 6 copies/ml. High-grade viraemia was defined as CMV DNA PCR copies >500 copies/ml 25 . The results of CMV PCR assays were not used for clinical care.
Assessments
Characteristics of the study population including demographic data, medical history, clinical and laboratory data were abstracted systematically in a data collection form. The primary endpoint was mortality and/or multiple organ failure (MOF) within 30 days of ICU admission. Time to onset of all events and endpoints were from the date of onset of bloodstream infection. Organ failure was assessed at baseline using Sequential Organ Failure Assessment (SOFA) score on a scale ranging from 0 to 4 for each of the six major organ systems, for an aggregate score of 0 to 24, with higher scores indicating more severe organ dysfunction 26 . Multiple organ failure was defined as ≥2 organ failure. The secondary outcomes were ICU-free days, ventilator-free days, MOFfree days and prolonged fever. 'Free days' (ICU-free days, ventilator-free days, MOF-free days) were considered as days alive and assigning all patients who died zero free days 27, 28 . Transfusion data collected were units of blood transfused subsequent to onset of BSI. Patients hospitalised in the ICU for more than 48 hours prior to the onset of BSI were considered as prolonged ICU admissions and those admitted within 48 hours of BSI were considered new ICU patients. Nosocomial (more than 48 hours after hospitalisation) and community-acquired (within 48 hours of hospitalisation) BSI were defined as previously reported. Prolonged febrile episodes were defined as episodes of fever of >38.3°C for >3 days with uncertain diagnosis despite appropriate cultures and investigation performed as standard of care.
Statistical analyses
The rate of CMV viraemia was calculated as the number of patients who had a positive CMV PCR at any time during the study period divided by the total number of CMV seropositive patients enrolled in the study. Continuous data were compared using Mann-Whitney U test. Categorical data were compared using chi-square test or Fisher's exact test when appropriate. Factors associated with CMV reactivation were further evaluated using a logistic regression model, with reactivation as the dependent variable and factors with univariate significance less than 0.1 as the predictors. This model was evaluated using the Hosmer-Lemeshow goodness-of-fit test and area under the receiver operator curve (ROC). Odds ratios and 95% confidence intervals were calculated. The primary and secondary outcomes of MOF and mortality were compared between patients with and without CMV viraemia using a logistic model in the same manner. ICU-, ventilator-and MOF-free days were evaluated using a regression model. Intercooled Stata (version 13, Stata-Corp) was used for all analyses. The average area under the curve (AUC) was estimated by using the time between PCR results as 'length' and the CMV viral load as the 'height'.
Results
CMV viraemia
In all, 220 eligible patients underwent assessment for CMV antibody, of whom 141 (64.1%) were seropositive. Of these, 28 were discharged from the ICU before the result of CMV antibody was available and 13 were excluded as the blood culture yielded a contaminant (coagulase-negative Staphylococci or Bacillus species). Therefore, of 100 evaluable patients, 20 (20%) had at least one positive CMV serum PCR and comprised the study population. Characteristics of the patients with and without CMV viraemia are shown in Table  1 . Of patients with CMV viraemia, 90% (18/20) had positive serum PCR at first CMV sampling (median six days, range 4-8 days after the onset of bacteraemia). Two patients had negative CMV PCR initially with subsequent blood samples on day 14 and day 15 yielding a positive result. Overall 43% of the BSI were nosocomial (BSI ≥48 hours post admission) and 57% were community-acquired. The geometric mean viral load in viraemic patients was 436 copies/ml at first detection and 542 copies/ml at the maximum. Only two patients had >10,000 copies/ml at any time during the study.
Risks for CMV viraemia
Patients with CMV viraemia were older (P=0.013), and had received more blood transfusions after the onset of bacteraemia (P=0.010). In all, 75% of the viraemic patients were older than 60 years and none were younger than 48 years (interquartile range [IQR] 60-78 years, overall range 48 to 85 years). In comparison, 16% (13/80) of the nonviraemic patients were younger than 48 years (IQR 53-67 years, overall range 18 to 90 years). Viraemic patients were also more likely to be on haemodialysis (P=0.056) and to have higher APACHE II (Acute Physiology and Chronic Health Evaluation) scores (P=0.071) ( Table 1 ). In logistic regression analysis with these variables in the model, age (odds ratio 1.05, 95% confidence interval [CI] 1.001-1.10, P=0.044) and blood transfusion (odds ratio 1.18, 95% CI 1.02-1.36, P=0.022) were significantly associated with CMV viraemia ( Table 1 ). The model had good fit with Hosmer-Lemeshow chi-square probability of 0.417 (failure to reject model) and an area under ROC curve of 0.764 indicating acceptable discrimination.
Overall outcomes
Primary outcome measures
Mortality and MOF rate in the patients was 16% (16/100) and 45% (45/100), respectively. Primary outcomes in the study population are shown in Table 2 . CMV viraemia was more likely to develop in patients who met the primary endpoint (mortality and/or MOF), however this was not statistically significant (odds ratio 1.59, 95% CI 0.43-5.97, P=0.49) ( Table 2 ). The model had a Hosmer-Lemeshow probability of 0.677 and an area under ROC curve of 0.847. Pneumonia as source of sepsis (25% versus 0%, P=0.0001) and bacteraemia due to S. aureus (39.6% versus 21.2%, P=0.045) was more likely occur in patients with the primary endpoint of mortality/MOF. Primary bacteraemia (19% versus 42%, P=0.011) on the other hand was less likely to occur in these patients. Patients who died or had MOF also had higher APACHE II scores (P=0.007), and had received more blood transfusions during the ICU stay (P=0.001). In the adjusted model, blood transfusion, APACHE II score, and S. aureus bacteraemia were significant predictors of poor outcome while primary bacteraemia was associated with better outcome. Correlates of mortality or MOF are shown in Tables 1S and 2S (see Supplementary file, AIC website).
Secondary outcome measures
Secondary outcomes included ICU-free days, ventilator-free days, MOF-free days and prolonged fever. Patients with CMV viraemia had significantly fewer ICU-free days (seven versus 18 days, median, P=0.023) and fewer ventilator-free days (15 versus 24 days, P=0.031) than in those without viraemia (Tables 3S and 4S , Supplementary file, AIC website). MOFfree days were fewer in patients with CMV viraemia (median 25.5 days versus 30 days, P=0.092), however, the difference was not statistically different (median 15 days versus 24.5 days, P=0.052). Prolonged fever was documented in only two patients and neither had CMV viraemia.
CMV viraemia kinetic data
Of 20 viraemic patients, an AUC was calculated for ten patients; the other ten had only a single positive blood sample for CMV before death or discharge. The AUC ranged from 2.4 to 6.075 [log copies/ml] over the duration of ICU stay. Patients with multi-organ failure had an average of 1 log higher level of AUC, however this was not statistically significant (P=0.109). AUC was also higher in patients with prolonged ICU stay prior to bacteraemia compared to those that were admitted to the ICU within 48 hours of the bacteraemia but again this was not statistically significant (P=0.125). None of the patients were treated with antivirals for CMV viraemia as the results of the test were not used for routine clinical care. Only two subjects had a reduction of greater than 0.5 log copies/ml prior to death or ICU discharge (0.54 and 0.56 log reduction, one week later). 
CMV viraemia in new ICU admissions
Of the overall study population, 70% (70/100) patients were new ICU patients whereas 30% (30/100) were already in the ICU at the onset of bacteraemia. New ICU patients were significantly less likely to develop CMV viraemia (12.9%, 9/70 versus 36.7%, 11/30, P=0.006) and less likely to have high-grade viraemia (5.7% versus 23.3%, P=0.010) compared to those who were already hospitalised in the ICU at the onset of sepsis (Table 3 ). New ICU admissions had more ICUfree days (P=0.018) and ventilator-free days (P=0.029) than prolonged ICU admissions.
Amongst new ICU patients, the rate of CMV viraemia was 12% (9/70). New ICU patients who developed CMV viraemia were more likely to be on haemodialysis (44% versus 15%, P=0.03), and had higher APACHE II score (29 versus 26.5, P=0.027) than those without CMV viraemia (Table 4 ).
Discussion
Several findings from our study are clinically relevant in the context of critically ill patients with sepsis. An estimated 751,000 cases of sepsis occur per year in the US and of these ~50% require ICU care 20, 21 . Furthermore, based on the US census projections, the number of cases of sepsis is projected to exceed one million by the year 2020 21 . This increase is more rapid than the anticipated population growth and is based on trends documenting disproportionate growth of the elderly in the US and a higher incidence of sepsis in older patients 21 . The total national US hospital cost associated with the care of patients with sepsis is ~US$16.7 billion of which US$8.7 billion (52.3%) is incurred by patients aged >65 years 21 .
Our data show that critically ill elderly patients with sepsis had significantly higher risk of CMV viraemia. Such an association is biologically plausible given that age-related decline in natural host responses or immune senescence is associated with impaired protective immunity against viruses 30 . The adaptive arm of host defence, particularly T-cell mediated immunity is more profoundly affected than innate responses. Ageing is associated with clonal expansion of latedifferentiated immune senescent CD8+ T-cells that are CMVspecific [31] [32] [33] . This increase in the number of dysfunctional cytomegalovirus-specific T-cells in the elderly is termed 'memory inflation' and is considered to be a compensatory mechanism to control the infection. Ultimately however, a point is reached where clonal exhaustion occurs that leads to shrinking repertoire and functional unresponsiveness of CD8+ T-cells and susceptibility to infection, impaired response against vaccinations, and lower survival 34 . In a previous study, CMV was associated with a 42% increase in the annual mortality rate (hazard ratio 1.42, 95% CI 1.11-1.76) corresponding to 3.7 years lower life expectancy from age 65 35 . In addition to CMV, human herpesvirus-6 reactivation may occur concurrently with CMV and may also be associated with adverse outcomes in critically ill patients 36 .
Blood transfusions have correlated with a risk of CMV infection in some but not all studies 5, 14 . Direct transmission of the virus from transfusions has the potential to transmit the virus although most infections in otherwise immunocompetent individuals are asymptomatic 37 . Since CMV infection may occur in critically ill patients with the receipt of leukocyte-depleted as well as non-depleted transfusions, it is proposed that transfusion-associated immunomodulation may have a role in the development of the infection. Transfusions down-regulate the host's immune surveillance mechanisms by impaired natural killer cell function, decreased macrophage phagocytic function, and suppression of lymphocyte proliferation 38, 39 . Potential adverse clinical effects of these changes in other host populations have included increased risk of cancer recurrence, postoperative infection and short-term mortality 38 . In our study, there was a significant association of CMV viraemia with transfusions. We however, note that this correlation was likely not causal as based on our study design, transfusion history collected was subsequent to the bacteraemia and viraemia. Thus viraemia preceded the transfusion and not vice versa. It is therefore plausible that patients receiving transfusions in the ICU were simply sicker or had greater physiologic severity of illness and comorbidities than patients not requiring transfusions.
A notable observation in our study is differences amongst critically ill septic patients who were ICU-bound, i.e. those moved to the ICU compared to those who had been in the ICU upon onset of sepsis. Despite similar severity of illness based on APACHE II scores at the time of sepsis, patients with prolonged ICU admission were significantly more likely to have CMV viraemia and to have high viral loads than the new ICU patients ( Table 3 ). Whether patients who become ill enough to warrant transfer to the ICU after the onset of sepsis have greater robustness of the immune system than those who become septic after considerable duration of critical illness is not known, but plausible. Additionally, our data suggest that protracted critical illness, as opposed to its severity, may be a more significant variable influencing the development of CMV viraemia in patients with sepsis. It is also plausible that other unmeasured confounding factors accounted for these observations in the patients with protracted illness. Although there was no difference in the overall mortality or organ failure rate, new ICU patients had fewer ICU-free days and ventilator-free days after the onset of sepsis. Given that ~37% of the patients with prolonged ICU admission had CMV viraemia and nearly one-fourth had high-grade viraemia suggests that directing interventions for CMV towards patients with protracted illness could be a consideration for approaches that target at-risk patients only.
Although CMV viraemia occurs frequently in critically ill patients, limited data exist on its association with fever. A Table 3 Differences
between patients with new versus prolonged ICU admission
Factor
In ICU >48 h prior to bacteraemia (n=30)
In ICU within 48h of bacteraemia (n=70) previous report documented that CMV viraemia was present in 17% of the critically ill patients with unexplained fever after ten days of hospitalisation 14 . Such an association could not be documented in our study. These differences could be due to the fact that testing for CMV viraemia in the prior study was not performed per protocol but rather based on clinical judgement of the care provider, and therefore symptomatic patients may have been more likely to be tested. In addition, CMV serologic status was not assessed in that study and therefore primary infections, which may be associated with a higher rate of clinically overt CMV disease, could not have been excluded 14 .
P-level
Our study has weaknesses that must be acknowledged. Although this study is amongst the largest reported series of CMV viraemia in critically ill septic patients, our sample size was small. Our findings therefore must be interpreted with caution. Our study focused on patients with sepsis due to BSI and therefore comparison of this cohort with patients who had sepsis due to other aetiologies is not available. Although data on the source and whether the BSI were nosocomial or community-acquired is presented, the antibiotic resistance profile of the organisms is not known. Additionally, formal assessments for immunosuppression or immunologic assays for antiviral immune impairment were not performed. Nevertheless, strengths of our study include the fact that clinical data and CMV sample collection was prospective and the laboratory assessments for CMV were performed in a blinded fashion by personnel who were independent of the clinical team. The homogeneity of the study population as opposed to a wider case-mix of critically ill patients has the potential to render our findings generalisable to patients with sepsis.
Assessment of critically ill patients who are at risk for developing CMV reactivation and for poor outcomes has implications relevant for optimising their outcomes. Our data show that older patients with sepsis are at a higher risk for developing CMV viraemia. CMV reactivation was associated with fewer ICU-free days, however overall mortality was not affected. Finally, patients already hospitalised in the ICU at the onset of sepsis had a higher rate of CMV reactivation and worse outcomes than new ICU patients. These data suggest that future interventions for CMV prevention using antiviral agents could conceivably be directed towards patients at highest risk, i.e. those with a protracted course of critical illness.
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